- Home
- BKNG vs GILD Comparison
BKNG vs GILD Comparison
Compare BKNG & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKNG
- GILD
- Stock Information
- Founded
- BKNG 1997
- GILD 1987
- Country
- BKNG United States
- GILD United States
- Employees
- BKNG N/A
- GILD N/A
- Industry
- BKNG Transportation Services
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BKNG Consumer Discretionary
- GILD Health Care
- Exchange
- BKNG Nasdaq
- GILD Nasdaq
- Market Cap
- BKNG 149.0B
- GILD 129.9B
- IPO Year
- BKNG 1999
- GILD 1992
- Fundamental
- Price
- BKNG $5,072.54
- GILD $96.91
- Analyst Decision
- BKNG Buy
- GILD Buy
- Analyst Count
- BKNG 30
- GILD 25
- Target Price
- BKNG $5,324.48
- GILD $109.00
- AVG Volume (30 Days)
- BKNG 245.6K
- GILD 8.7M
- Earning Date
- BKNG 04-29-2025
- GILD 04-24-2025
- Dividend Yield
- BKNG 0.76%
- GILD 3.26%
- EPS Growth
- BKNG 20.24
- GILD 1118.07
- EPS
- BKNG 161.59
- GILD 4.73
- Revenue
- BKNG $24,086,000,000.00
- GILD $28,735,000,000.00
- Revenue This Year
- BKNG $8.24
- GILD $1.88
- Revenue Next Year
- BKNG $8.38
- GILD $3.95
- P/E Ratio
- BKNG $31.44
- GILD $20.47
- Revenue Growth
- BKNG 9.47
- GILD 4.68
- 52 Week Low
- BKNG $3,180.00
- GILD $62.07
- 52 Week High
- BKNG $5,337.24
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- BKNG 60.15
- GILD 34.47
- Support Level
- BKNG $5,132.62
- GILD $95.30
- Resistance Level
- BKNG $5,238.34
- GILD $107.17
- Average True Range (ATR)
- BKNG 129.00
- GILD 3.66
- MACD
- BKNG 29.97
- GILD -0.73
- Stochastic Oscillator
- BKNG 77.62
- GILD 24.95
About BKNG Booking Holdings Inc.
Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, Rentalcars.com, Kayak, and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).